|本期目录/Table of Contents|

[1]刘宇,曹清心,高玲.丹参川芎嗪注射液对急性ST段抬高型心肌梗死经皮冠状动脉介入术后患者的心肌保护作用机制[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):468-472.[doi:10.3969/j.issn.1672-271X.2020.05.004]
　LIU Yu,CAO Qing-xin,GAO Ling.Effect of Danshen Chuanxiong Injection on myocardial protection and its mechanism in patients with acute ST segment elevation myocardial infarction after PCI[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(5):468-472.[doi:10.3969/j.issn.1672-271X.2020.05.004]
点击复制

丹参川芎嗪注射液对急性ST段抬高型心肌梗死经皮冠状动脉介入术后患者的心肌保护作用机制()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第22卷
期数:
2020年5期
页码:
468-472
栏目:
临床研究
出版日期:
2020-09-09

文章信息/Info

Title:
Effect of Danshen Chuanxiong Injection on myocardial protection and its mechanism in patients with acute ST segment elevation myocardial infarction after PCI
作者:
刘宇; 曹清心; 高玲
作者单位：210008南京，南京大学医学院附属鼓楼医院心内科（刘宇、高玲）；210002南京，东部战区疾病预防控制中心（曹清心）
Author(s):
LIU Yu1; CAO Qing-xin2; GAO Ling1
（1. Department of Cardiology，the Affiliated Drumtower Hospital of Nanjing University, Nanjing 210008，Jiangsu，China; 2. Eastern Theater Centers for Disease Control and Prevention, Nanjing 210002，Jiangsu，China)
关键词:
丹参川芎嗪注射液; 急性ST段抬高型心肌梗死; 经皮冠状动脉介入术; 心肌保护
Keywords:
Danshen Chuanxiong Injection;  acute ST segment elevation myocardial infarction;  percutaneous coronary intervention;  myocardial protection
分类号:
R541.4
DOI:
10.3969/j.issn.1672-271X.2020.05.004
文献标志码:
A
摘要:
目的探讨丹参川芎嗪注射液对急性ST段抬高型心肌梗死经皮冠状动脉介入术（PCI）术后患者心肌保护作用及其机制。方法选择2017年6月至2019年6月期间南京大学医学院附属鼓楼医院收治的急性ST段抬高型心肌梗死PCI术后患者122例，依据随机数字表法分为联合组与对照组各61例。2组患者均行PCI术治疗，术前口服阿司匹林肠溶片和硫酸氢氯吡格雷片。对照组术后给予常规治疗，联合组在对照组基础上给予丹参川芎嗪注射液治疗。2组疗程均为14 d。比较2组治疗前后心功能变化[左心室射血反射（LVEF）、左室舒张末期内径（LVEDD）]，血浆N末端脑钠肽前体（NT-proBNP）和心肌酶指标[肌酸激酶同工酶（CK-MB）和肌钙蛋白T（cTnT）]变化，炎症因子[血管内皮生长因子（VEGF）、白介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）]变化，血管内皮功能和氧化应激变化，及不良反应发生情况。结果联合组治疗后LVEF[（56.47±5.13）%]高于对照组[（50.38±3.27）%]，而LVEDD[（45.32±1.98）mm]低于对照组[（48.82±2.15）mm]，差异均有统计学意义（P<0.05）。联合组治疗后血浆NT-proBNP[（497.93±64.52）ng/mL]和CK-MB[（12.31±2.76）ng/mL]低于对照组[（789.83±120.24）ng/mL、（19.83±4.35）ng/mL]，而cTnT[（0.38±0.09）ng/mL]高于对照组[（0.25±0.07）ng/mL]，差异均有统计学意义（P<0.05）。联合组治疗后血浆VEGF[（118.98±15.46）mg/L]、IL-6[（8.74±1.42）pg/ml]和TNF-α[（10.27±1.58）pg/mL]低于对照组[（184.35±21.09）mg/L、（11.27±2.09）pg/mL、（15.42±2.39）pg/mL]，差异均有统计学意义（P<0.05）。联合组治疗后血浆ET-1[（43.56±6.87）μmol/L]低于对照组[（62.65±8.97）μmol/L]，SOD[（93.24±7.58）U/mL]高于对照组[（78.93±4.87）U/mL]，MDA[（6.84±1.39）μmol/L]低于对照组[（8.97±1.54）μmol/L],差异均有统计学意义（P<0.05）。2组治疗期间均未发生明显不良反应。结论丹参川芎嗪注射液对急性ST段抬高型心肌梗死PCI术后具有良好心肌保护作用，其机制可能与减轻炎症反应及改善血管内皮功能和氧化应激有关。
Abstract:
ObjectiveTo investigate the myocardial protective effect and mechanism of Danshen Chuanxiong Injection on patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention (PCI).MethodsFrom June2017 to June 2019, 122 patients with acute ST segment elevation myocardial infarction after PCI were randomly divided into combined group (61 cases) and control group (61 cases). Patients in both groups were treated with PCI, and aspirin enteric coated tablets and clopidogrel bisulfate tablets were taken before operation. The patients in the combined group were treated with Danshen Chuanxiong Injection on the basis of the control group. The course of treatment in both groups was 14 days. The changes of cardiac function (LVEF, LVEDd), N-terminal pro brain natriuretic peptide (NT proBNP), myocardial enzyme index (CK-MB, cTnT), inflammatory factors (VEGF, IL-6 and TNF-α), the changes in endothelial function, oxidative stress, and adverse reactions were compared before and after treatment.ResultsAfter treatment, the combined group LVEF (56.47%±5.13%) was higher than that in the control group (50.38%±3.27%), while LVEDd (45.32%±1.98%) mm was lower than that in the control group (48.82±2.15) mm (P<0.05). After treatment, the combined group NT proBNP (497.93±64.52) ng/mL and CK-MB (12.31±2.76) ng/mL were lower than those in the control group (789.83±120.24) ng/mL and (19.83±4.35) ng/mL, while cTnT (0.38±0.09) ng/mL was higher than those in the control group (0.25±0.07) ng/mL (P<0.05). After treatment, the combined group levels of VEGF (118.98±15.46) mg/L, IL-6 (8.74±1.42) pg/mL and TNF-α (10.27±1.58) pg/mL were lower than those in the control group (184.35±21.09) mg/L, (11.27±2.09) pg/mL and (15.42±2.39) pg/mL (P<0.05). After treatment, the combined group level of ET-1 (43.56±6.87)μmol/L was lower than that in the control group (62.65±8.97) (P<0.05). After treatment, the combined group plasma SOD (93.24±7.58) U/mL was higher than that in the control group (78.93±4.87) U/mL, while the MDA (6.84±1.39) μmol/L was lower than that in the control group (8.97±1.54) μmol/L (P<0.05). No significant adverse reactions occurred in two groups.ConclusionDanshen Chuanxiong Injection has a good myocardial protective effect on acute ST segment elevation myocardial infarction after PCI, and its mechanism may be related to the reduction of inflammatory response, improvement of vascular endothelial function and oxidative stress, and can improve myocardial enzymes, reduce NT proBNP, and have no obvious adverse reactions, so it is safe to use.

参考文献/References:

[1]Malick W,Fried JA,Masoumi A,et al.Comparison of the Hemodynamic Response to Intra-Aortic Balloon Counterpulsation in Patients With Cardiogenic Shock Resulting from Acute Myocardial Infarction Versus Acute Decompensated Heart Failure[J].Am J Cardiol,2019,124(12):1947-1953.
[2]杨文雯,赵敏,任芳.急性ST段抬高型心肌梗死患者急诊PCI术后不良心脏事件危险因素分析[J].中国医学前沿杂志（电子版）,2019,11(7):100-104.
[3]Sud K,Haddadin F,Tsutsui RS,et al. Readmissions in ST-Elevation Myocardial Infarction and Cardiogenic Shock (from Nationwide Readmission Database[J].Am J Cardiol,2019,124(12):1841-1850.
[4]许新民,崔海明,杨靖,等.丹红注射液对急性心肌梗死直接经皮冠状动脉介入术后缺血心肌的保护作用J]. 东南国防医药,2015,17(5):451-454.
[5]张敏秀,贾辛未.术前口服羟考酮对急性ST段抬高型心肌梗死患者急诊PCI术后无复流的影响[J].山东医药,2019,59(23):54-57.
[6]吕磊, 张洁, 殷宇刚,等.川芎嗪减轻大鼠心肌缺血再灌注损伤后心肌细胞凋亡及其机制研究[J]. 东南国防医药,2016，18(4):361-364.
[7]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2015,43(5):380-393.
[8]Song PS,Hahn JY,Gwon HC,et al.Multivessel percutaneous coronary intervention in patients with acute myocardial infarction and severe renal dysfunction[J].EuroIntervention,2019,15(11):e1014-e1021.
[9]Caldentey G, García De Frutos P, Cristóbal H,et al. Serum levels of Growth Arrest-Specific 6 protein and soluble AXL in patients with ST-segment elevation myocardial infarction[J].Eur Heart J Acute Cardiovasc Care,2019,8(8):708-716.
[10]周国亮,王艳茹,张月婵,等.急性ST段抬高型心肌梗死患者PCI术应用替格瑞洛对心功能变化及不良心脑血管事件发生的影响[J].解放军医药杂志,2019,31(8):86-89.
[11]Khoury S, Margolis G, Rozenbaum Z, et al. Acute renal impairment in older adults treated with percutaneous coronary intervention for ST-segment elevation myocardial infarction[J]. Coron Artery Dis, 2019, 30(8):564-568.
[12]陈涛,周致远,袁明,等.腺苷联合替罗非班对老年急性ST段抬高型心肌梗死PCI术后再灌注损伤及心功能的保护作用研究[J].中西医结合心脑血管病杂志,2019,17(18):2803-2806.
[13]郝鹏,冯斯婷,甄雷,等.SYNTAX Ⅱ评分对急性ST段抬高型心肌梗死患者直接PCI术后无复流的预测价值[J].首都医科大学学报,2019,40(5):744-748.
[14]吴玉成,李云升,桑运锋, 等.不同剂量阿托伐他汀对急性ST段抬高型心肌梗死患者急诊PCI术后无复流现象发生和心功能的影响[J].临床和实验医学杂志,2019,18(21):2307-2310.
[15]李静,高天林,宋辉.急性ST段抬高型心肌梗死患者PCI术后替罗非班应用的效果分析[J].湖南师范大学学报（医学版）,2019,16(5):161-164.
[16]孙雨华,张正海,张海滨,等.丹参川芎嗪注射液联合替罗非班治疗急性ST段抬高型心肌梗死的临床研究[J].现代药物与临床,2016,31(6):776-779.
[17]马仙红,张瑜.银杏达莫与丹参川芎嗪注射液治疗老年急性心肌梗死的临床对照研究[J].药物评价研究,2017,40(10):1449-1452.
[18]张洁,王峰.丹参川芎嗪注射液联合尿激酶治疗急性心肌梗死的疗效观察[J].现代药物与临床,2018,33(3):487-491.
[19]于霏,王琦,雷明明,等.急性心肌梗死患者冠状动脉Gensini评分与NT-proBNP和左心结构及功能的研究[J].中国医师杂志,2018,20(8):1202-1204.
[20]李军涛,田荣英.心肌酶谱、肌钙蛋白、肌红蛋白与脑钠肽联合检测在早期急性心肌梗死诊断中的临床价值[J].河北医药,2019,41(12):1779-1783.
[21]祝聪聪,夏璐,胡良炎.围术期应用替格瑞洛与氯吡格雷对急性心肌梗死患者PCI术 后血小板功能及炎症因子的影响[J].湖南师范大学学报（医学版）,2019,16(1):116-119.
[22]顾冰,王伟,连蕊,等.血清丁酰胆碱酯酶活性与急性心肌梗死患者经皮冠状动脉介入治疗术后炎症因子及短期预后的相关性[J].临床内科杂志,2019,36(6):394-398.
[23]雷晓敏,曹蕊.替罗非班对冠心病PCI术患者血管内皮功能及MMP-9的影响[J].海南医学,2019,30(22):2872-2875.
[24]张洁,艾芬.柴胡皂苷D对急性心肌梗死大鼠血流动力学和心肌氧化应激损伤的保护作用[J].医学分子生物学杂志,2019,16(1):81-86.
[25]王思艳,郭明凤.阿替洛尔与卡维地洛对急性心肌梗死患者炎症因子和氧化应激的影响[J].国际检验医学杂志,2019,40(17):2120-2122,2127.

相似文献/References:

[1]黄华敏.心电图QRS-T夹角与P波离散度对STEMI患者急诊PCI预后的评估价值[J].医学研究与战创伤救治(原医学研究生学报),2022,24(3):257.[doi:10.3969/j.issn.1672-271X.2022.03.007]
　HUANG Hua-min.Evaluation value of ECG QRS-T angle and P-wave dispersion on the prognosis of emergency PCI in patients with STEMI[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(5):257.[doi:10.3969/j.issn.1672-271X.2022.03.007]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（81700396）
更新日期/Last Update: 2020-09-09